Cargando…

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

BACKGROUND: Serum carcinoembryonic antigen (CEA) levels are a predictor of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) efficacy and are associated with epidermal growth factor receptor (EGFR) gene mutations. However, the clinical significance of plasma CEA level changes dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yuan, Song, PingPing, Li, Hui, Jia, Hui, Zhang, BaiJiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512835/ https://www.ncbi.nlm.nih.gov/pubmed/28705152 http://dx.doi.org/10.1186/s12885-017-3474-3

Ejemplares similares

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Metastatic Lung Adenocarcinoma Harboring an EGFR-Activating Mutation in a Heart Transplant Recipient
por: Zambrano Mendoza, Elizabeth, et al.
Publicado: (2017)

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
por: Qin, Hongyue, et al.
Publicado: (2022)

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
por: Chen, R.-L., et al.
Publicado: (2017)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation
por: Ohtsuka, Kouki, et al.
Publicado: (2019)

Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations
por: He, Di, et al.
Publicado: (2020)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma
por: Zhao, Jikai, et al.
Publicado: (2017)

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations
por: Kim, In Ae, et al.
Publicado: (2021)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
por: Kogure, Yoshihito, et al.
Publicado: (2015)

The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels
por: Xie, Hai-Lun, et al.
Publicado: (2019)

Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report
por: Zhong, Rui, et al.
Publicado: (2019)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

CEA Decline Predicts Tumor Regression and Prognosis in Locally Advanced Rectal Cancer Patients with Elevated Baseline CEA
por: Cai, Zerong, et al.
Publicado: (2020)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
por: Xu, Hui, et al.
Publicado: (2020)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report
por: Moriya, Rika, et al.
Publicado: (2017)

Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
por: Song, Xinyu, et al.
Publicado: (2017)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
por: Pei, Guotian, et al.
Publicado: (2020)

Diaphragmatic hernia during treatment of lung cancer harboring an EGFR mutation
por: Konno-Yamamoto, Aya, et al.
Publicado: (2021)

The CEA(−/lo) colorectal cancer cell population harbors cancer stem cells and metastatic cells
por: Yan, Chang, et al.
Publicado: (2016)

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma
por: Nie, Yunqiang, et al.
Publicado: (2017)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
por: Sun, Ruizhu, et al.
Publicado: (2022)

Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report
por: An, Ning, et al.
Publicado: (2019)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas
por: Nie, Yunqiang, et al.
Publicado: (2019)

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
por: Xiong, Yicheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1oo6bkbt395timtd780a6f3r8v